KLK2 and prostate carcinoma: Robust expression of KLK2 was noted across the prostate cancer disease continuum, with homogeneous expression in LPC and mHSPC and increased heterogeneity in heavily pretreated mCRPC tissue samples (Fig. 1B; Supplementary Fig. S1).